Elite Pharmaceuticals, Inc. reported significant financial growth in its fiscal year ending March 31, 2026, with total revenues reaching $148.9 million, a 77% increase from $84.0 million in the previous year. This surge in revenue was primarily driven by the successful launch of new products, including Oxy APAP tablets, and increased sales of existing products like Naltrexone and Phentermine tablets. Manufacturing fees contributed $147.8 million to total revenue, reflecting an 80% increase, while licensing fees decreased by 48% to $1.1 million, attributed to a strategic shift away from licensing to focus on direct marketing under the Elite label.
The company's cost of manufacturing also rose, totaling $73.8 million, which represents a 68% increase compared to the prior year. This rise was closely linked to the increased volume of products sold. Despite the higher costs, Elite Pharmaceuticals achieved a gross profit of $75.0 million, resulting in a gross profit margin of 50%, up from 48% in the previous year, indicating improved profitability driven by a favorable product mix.
Operating expenses increased by 26% to $25.9 million, largely due to a 95% rise in general and administrative expenses, which were influenced by higher employee compensation and operational support costs. Research and development expenses decreased by 28% to $5.7 million, reflecting a reallocation of resources towards commercial operations. The company reported an income from operations of $49.1 million, a substantial increase from $19.6 million in the previous fiscal year.
Looking ahead, Elite Pharmaceuticals is focused on expanding its product portfolio and enhancing its market presence. The company recently launched generic methadone tablets and filed an Abbreviated New Drug Application for a new anticoagulant product. However, it faces ongoing challenges, including regulatory scrutiny and potential litigation related to its opioid products. The company is also addressing material weaknesses in its internal controls over financial reporting, which could impact its operational efficiency and financial reporting accuracy if not remediated effectively.
Overall, Elite Pharmaceuticals is positioned for growth, but it must navigate a complex regulatory environment and manage operational risks to sustain its financial performance and capitalize on new market opportunities.
About ELITE PHARMACEUTICALS INC /NV/
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and manufacturing oral, controlled-release, and generic drugs. It owns a broad portfolio of approved generic products across various therapeutic categories, utilizing proprietary technology and strategic licensing agreements. The company emphasizes product development, manufacturing, and licensing to serve healthcare providers and patients in the U.S. and abroad, with a focus on high-barrier-to-entry generics and abuse-deterrent formulations.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.